Jade Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $844.33M
- P/E (TTM)
- –
- Dividend yield
- –
About Jade Biosciences
Pharmaceutical Preparations, SIC 2834
Jade Biosciences is a clinical-stage biopharmaceutical company that discovers and develops biologic therapies to treat autoimmune disorders. The company focuses on monoclonal antibody candidates engineered to improve potency and pharmacokinetic properties over existing alternatives. Its lead product candidate, JADE101, targets a cytokine called APRIL to treat IgA nephropathy, a progressive kidney disease. Its second product candidate, JADE201, targets the BAFF receptor through cellular cytotoxicity and signaling pathway inhibition to address conditions such as rheumatoid arthritis. A third development program, JADE301, targets an undisclosed biological pathway. The company directs its investigational therapies toward patients suffering from serious autoimmune conditions.
The company maintains its corporate headquarters in Waltham, Massachusetts. Its geographic presence includes clinical trial activity in New Zealand, where it evaluates healthy volunteers, alongside laboratory-stage research and development. Additionally, the company collaborates with external biotechnology partners for discovery and preclinical research services.
Summary of the business section of Jade Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Jade Biosciences, Inc.
- Headquarters
- Waltham, MA
- Address
- 221 Crescent St., Building 23, Suite 105 02453
- Phone
- (781) 312-3013
- Website
- jadebiosciences.com
- Employees
- 55, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- JBIO
- Exchange
- Nasdaq
- IPO date
- Jun 30, 2021
- Shares outstanding
- 64M, Aug 3, 2026
- Public float
- $289.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-35 reverse, Apr 29, 2025
- SEC CIK
- 1798749
- CUSIP
- 008064206
- ISIN
- US0080642061
- EIN
- 83-1377888
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Tom Frohlich | Chief Executive Officer, Director | 86,331 |
| Elizabeth Balta | See Remarks | 28,125 |
| Bradford D. Dahms | Chief Financial Officer | 37,813 |
| Andrew James King | See Remarks | 386,113 |
| Hetal Kocinsky | Chief Medical Officer | – |
| Jonathan Quick | See Remarks | – |
| Mark Eisner | Director | – |
| Eric Dobmeier | Director | – |
| Erin Lavelle | Director | – |
| Healthcare Co-Invest IV L.P. Fairmount | Director | – |
| Healthcare Fund II L.P. Fairmount | Director | 4,553,494 |
| Tomas Kiselak | Director | – |
| Funds Management LLC Fairmount | Director | – |
| Peter Evan Harwin | Director | – |
| Lawrence Otto Klein | Director | 86,215 |
| Christopher W. Cain | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 55 full-time employees, 15 of whom have Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 14, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 1, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 1, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 30, 2025 | Name change | Name changed from Aerovate Therapeutics, Inc. to Jade Biosciences, Inc. |
| Dec 3, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Oct 17, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 30, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 25, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |